logo
  

Walgreens Boots Alliance Sells AmerisourceBergen Shares For About $1.0 Bln

Walgreens Boots Alliance Inc. (WBA) said that it has sold shares of AmerisourceBergen Corp. (ABC) for proceeds of about $1.0 billion.

Walgreens Boots said it sold about $0.8 billion of AmerisourceBergen shares pursuant to Rule 144, and a concurrent share repurchase by AmerisourceBergen for proceeds of about $0.2 billion.

Walgreens Boots Alliance's ownership of AmerisourceBergen's common stock has decreased from about 20 percent to approximately 17 percent.

Walgreens Boots Alliance said it will use proceeds from the share sales primarily for debt paydown and the funding of the company's strategic priorities, including the definitive agreement for VillageMD to acquire Summit Health-CityMD.

Walgreens noted that the sale has no impact to the long-term partnership between the two companies. Chief Operating Officer, International of Walgreens Boots Alliance, Ornella Barra, will continue to serve on AmerisourceBergen's Board of Directors.

In a separate press release, AmerisourceBergen confirmed that it agreed to repurchase shares of its common stock from Walgreens Boots Alliance Holdings LLC in the amount of about $200 million in concurrence with Walgreens Boots Alliance's sale of AmerisourceBergen shares pursuant to Rule 144.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
The U.S. Consumer Product Safety Commission or CPSC announced recall of thousands of children's Robes made in China and sold exclusively on Amazon.com by various companies. The recalled robes fail to meet the federal flammability standards for children's sleepwear, posing a risk of burn injuries to children. Further, citing the same concerns, Paper Cape children's pajamas manufactured in Peru ... Health services company Cigna Corp. reported Friday higher profit in its fourth quarter reflecting growth in both Evernorth and Cigna Healthcare segments. Adjusted earnings and topline beat market estimates. Looking ahead for fiscal 2023, the company projects adjusted earnings and adjusted revenues to be higher than last year, but below market view. French drug major Sanofi SA reported Friday higher profit in its fourth quarter with strong revenue growth mainly with strong sales of Dupixent. Looking ahead for fiscal 2023, the company projects higher business earnings, but the expected growth is slower than recorded in fiscal 2022. Sanofi shares were losing around 4 percent in the morning trading in Paris as well as in pre-market activity...
Follow RTT